Joe is the Chief Scientific Officer and Head of Discovery at Denali Therapeutics, a biotechnology company dedicated to developing innovative treatments for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS, and rare genetic disorders. In this role, he oversees Denali’s scientific strategy and preclinical portfolio, resulting the advancement of ten Denali originated molecules into clinical trials. These include both small molecules and biotherapeutics that utilize Denali’s proprietary Transport Vehicle (TV) platform to enable biologics to effectively cross the blood–brain barrier. Before joining Denali in early 2016, Joe spent nine years at Genentech, where he played a key role in shaping the company’s neuroscience disease area strategy and portfolio. He holds a Bachelor of Science from the University of California, San Diego, a Ph.D. from Johns Hopkins University School of Medicine, and completed a postdoctoral fellowship at the Salk Institute.
